These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2481953)

  • 1. Augmentation of kallikrein and plasmin inhibition capacity by aprotinin using a new assay to monitor therapy.
    Gallimore MJ; Fuhrer G; Heller W; Hoffmeister HE
    Adv Exp Med Biol; 1989; 247B():55-60. PubMed ID: 2481953
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetics of inhibition of human plasma kallikrein by a site-specific modified inhibitor Arg15-aprotinin: evaluation using a microplate system and comparison with other proteases.
    Scott CF; Wenzel HR; Tschesche HR; Colman RW
    Blood; 1987 May; 69(5):1431-6. PubMed ID: 2436687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin.
    Ray MJ; Marsh NA
    Thromb Haemost; 1997 Sep; 78(3):1021-6. PubMed ID: 9308747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the kallikrein-kinin-system after different dose regimen of aprotinin during cardiopulmonary bypass operation.
    Heller W; Fuhrer G; Gallimore MJ; Michel J; Hoffmeister HE
    Adv Exp Med Biol; 1989; 247B():43-8. PubMed ID: 2481948
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on components of the plasma kallikrein-kinin system in patients undergoing cardiopulmonary bypass.
    Fuhrer G; Gallimore MJ; Heller W; Hoffmeister HE
    Adv Exp Med Biol; 1986; 198 Pt B():385-91. PubMed ID: 2433915
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of covalent binding of aprotinin with a polysaccharide carrier on its inhibition of kallikrein from human plasma, porcine pancreatic kallikrein and trypsin].
    Larionova NI; Makevnina LG; Nartikova VF; Paskhina TS
    Biokhimiia; 1987 May; 52(5):825-31. PubMed ID: 2439135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [On the kallikrein-trypsin-inhibitor].
    Trautschold I; Werle E; Zickgraf-Rüdel G
    Arzneimittelforschung; 1966 Nov; 16(11):1507-15. PubMed ID: 4233517
    [No Abstract]   [Full Text] [Related]  

  • 9. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of kallikrein inhibitors in potatoes. II. Effect of potato kallikrein inhibitors on various kallikreins and other proteases.
    Hojima Y; Moriya H; Moriwaki C
    J Biochem; 1971 Jun; 69(6):1027-32. PubMed ID: 4253726
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of chronic urticaria with a proteinase (kallikrein) inhibitor.
    Berova N; Petkov I; Andreev VC
    Br J Dermatol; 1974 Apr; 90(4):431-4. PubMed ID: 4274689
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of textilinin-1 with aprotinin as serine protease inhibitors and as antifibrinolytic agents.
    Flight S; Johnson L; Trabi M; Gaffney P; Lavin M; de Jersey J; Masci P
    Pathophysiol Haemost Thromb; 2005; 34(4-5):188-93. PubMed ID: 16707925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [EXPERIMENT WITH A PLASMIN PREPARATION BY USING THE CASIN SPLITTING TEST: THE ACTION OF PLASMIN-NOVO AND ITS INHIBITION WITH EPSILON-AMINOCAPROIC ACID AND TRASYLOL].
    BERGHOFF A; GLATZEL H
    Thromb Diath Haemorrh; 1964 Dec; 12():418-24. PubMed ID: 14254701
    [No Abstract]   [Full Text] [Related]  

  • 14. The inhibitory effects of p-carbethoxyphenyl epsilon-guanidinocaproate and trasylol on the esterolysis by various kallikreins, plasmin and plasmin-alpha 2-macroglobulin complex.
    Tamura Y; Ishimaru K; Mori H; Hirado M; Fujii S
    Tokushima J Exp Med; 1979 Dec; 26(3-4):81-3. PubMed ID: 94710
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of recombinant aprotinin on t-PA-induced bleeding in rats.
    Erhardtsen E; Bregengaard C; Hedner U; Diness V; Halkjaer E; Petersen LC
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):707-12. PubMed ID: 7532446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprotinin: mechanism of action and therapeutical uses.
    Fussi F
    Boll Chim Farm; 1980 Nov; 119(11):631-46. PubMed ID: 6164378
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of selective inhibitors against plasma kallikrein.
    Teno N; Wanaka K; Okada Y; Tsuda Y; Okamoto U; Hijikata-Okunomiya A; Naito T; Okamoto S
    Chem Pharm Bull (Tokyo); 1991 Nov; 39(11):2930-6. PubMed ID: 1839246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Behavior of the kallikrein inhibitor against enzymes, 3. Behavior of the kallikrein inhibitor from bovine lung against proteases].
    Kraut H; Bhargava N
    Hoppe Seylers Z Physiol Chem; 1967 Nov; 348(11):1498-9. PubMed ID: 4231141
    [No Abstract]   [Full Text] [Related]  

  • 19. Textilinin-1, an alternative anti-bleeding agent to aprotinin: Importance of plasmin inhibition in controlling blood loss.
    Flight SM; Johnson LA; Du QS; Warner RL; Trabi M; Gaffney PJ; Lavin MF; de Jersey J; Masci PP
    Br J Haematol; 2009 Apr; 145(2):207-11. PubMed ID: 19236611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of heparin on proteolytic activities in human plasma.
    Kongsgaard UE; Aasen AO; Smith-Erichsen N; Bjørnskau L
    Eur Surg Res; 1992; 24(2):119-28. PubMed ID: 1374715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.